Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1999 Jun;52(6):440–444. doi: 10.1136/jcp.52.6.440

Downregulation of p21/WAF1 is related to advanced and dedifferentiated laryngeal squamous cell carcinoma.

P Hirvikoski 1, J K Kellokoski 1, E J Kumpulainen 1, J A Virtaniemi 1, R T Johansson 1, V M Kosma 1
PMCID: PMC501431  PMID: 10562812

Abstract

AIM: To analyse p21/WAF1 expression and its relation to p53, apoptosis, cell proliferation, clinicopathological characteristics, and patient survival in human laryngeal squamous cell carcinoma. METHODS: Primary tumours for analyses were obtained from 172 patients with complete follow up data. All patients were treated between 1975 and 1995. Immunohistochemistry was used to evaluate the expression of p21/WAF1, bcl-2, and p53 proteins. The proliferative activity was determined using Ki67 and PCNA antibodies as well as volume corrected mitotic count (M/V index). Volume corrected apoptotic count (A/V index) was determined using an enzymatic in situ cell death detection kit based on the TUNEL method. RESULTS: High p21 expression was significantly related to high p53 and normal bcl-2 expressions as well as low mitotic count. No association was noticed between p21 expression and apoptotic rate. A significant inverse correlation between p21 expression and advanced stage and poor differentiation was observed, but p21 expression showed no correlation with survival. CONCLUSIONS: The expression of p21 was associated with tumour stage, histopathological grade, node status, and mitotic count, which may indicate a role for p21 in the progression of laryngeal squamous cell carcinoma.

Full text

PDF
440

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Backe J., Gassel A. M., Hauber K., Krebs S., Bartek J., Caffier H., Kreipe H. H., Müller-Hermelink H. K., Dietl J. p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein. Int J Gynecol Pathol. 1997 Oct;16(4):361–368. doi: 10.1097/00004347-199710000-00011. [DOI] [PubMed] [Google Scholar]
  2. Brugarolas J., Bronson R. T., Jacks T. p21 is a critical CDK2 regulator essential for proliferation control in Rb-deficient cells. J Cell Biol. 1998 Apr 20;141(2):503–514. doi: 10.1083/jcb.141.2.503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Byrne R. L., Horne C. H., Robinson M. C., Autzen P., Apakama I., Bishop R. I., Neal D. E., Hamdy F. C. The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Br J Urol. 1997 Feb;79(2):190–195. doi: 10.1046/j.1464-410x.1997.03399.x. [DOI] [PubMed] [Google Scholar]
  4. Cox L. S. Multiple pathways control cell growth and transformation: overlapping and independent activities of p53 and p21Cip1/WAF1/Sdi1. J Pathol. 1997 Oct;183(2):134–140. doi: 10.1002/(SICI)1096-9896(199710)183:2<134::AID-PATH960>3.0.CO;2-D. [DOI] [PubMed] [Google Scholar]
  5. DiGiuseppe J. A., Redston M. S., Yeo C. J., Kern S. E., Hruban R. H. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol. 1995 Oct;147(4):884–888. [PMC free article] [PubMed] [Google Scholar]
  6. Diab S. G., Yu Y. Y., Hilsenbeck S. G., Allred D. C., Elledge R. M. WAF1/CIP1 protein expression in human breast tumors. Breast Cancer Res Treat. 1997 Apr;43(2):99–103. doi: 10.1023/a:1005752829260. [DOI] [PubMed] [Google Scholar]
  7. Dimri G. P., Nakanishi M., Desprez P. Y., Smith J. R., Campisi J. Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein. Mol Cell Biol. 1996 Jun;16(6):2987–2997. doi: 10.1128/mcb.16.6.2987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Doglioni C., Pelosio P., Laurino L., Macri E., Meggiolaro E., Favretti F., Barbareschi M. p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. J Pathol. 1996 Jul;179(3):248–253. doi: 10.1002/(SICI)1096-9896(199607)179:3<248::AID-PATH571>3.0.CO;2-6. [DOI] [PubMed] [Google Scholar]
  9. Dolcetti R., Doglioni C., Maestro R., Gasparotto D., Barzan L., Pastore A., Romanelli M., Boiocchi M. p53 over-expression is an early event in the development of human squamous-cell carcinoma of the larynx: genetic and prognostic implications. Int J Cancer. 1992 Sep 9;52(2):178–182. doi: 10.1002/ijc.2910520204. [DOI] [PubMed] [Google Scholar]
  10. Erber R., Klein W., Andl T., Enders C., Born A. I., Conradt C., Bartek J., Bosch F. X. Aberrant p21(CIP1/WAF1) protein accumulation in head-and-neck cancer. Int J Cancer. 1997 Aug 22;74(4):383–389. doi: 10.1002/(sici)1097-0215(19970822)74:4<383::aid-ijc4>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  11. Gomez-Manzano C., Fueyo J., Kyritsis A. P., McDonnell T. J., Steck P. A., Levin V. A., Yung W. K. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst. 1997 Jul 16;89(14):1036–1044. doi: 10.1093/jnci/89.14.1036. [DOI] [PubMed] [Google Scholar]
  12. Gomyo Y., Ikeda M., Osaki M., Tatebe S., Tsujitani S., Ikeguchi M., Kaibara N., Ito H. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer. 1997 Jun 1;79(11):2067–2072. doi: 10.1002/(sici)1097-0142(19970601)79:11<2067::aid-cncr3>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  13. Haapasalo H., Pesonen E., Collan Y. Volume corrected mitotic index (M/V-INDEX). The standard of mitotic activity in neoplasms. Pathol Res Pract. 1989 Nov;185(5):551–554. doi: 10.1016/S0344-0338(89)80191-8. [DOI] [PubMed] [Google Scholar]
  14. Haines D. S., Landers J. E., Engle L. J., George D. L. Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol Cell Biol. 1994 Feb;14(2):1171–1178. doi: 10.1128/mcb.14.2.1171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Harada N., Gansauge S., Gansauge F., Gause H., Shimoyama S., Imaizumi T., Mattfeld T., Schoenberg M. H., Beger H. G. Nuclear accumulation of p53 correlates significantly with clinical features and inversely with the expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in pancreatic cancer. Br J Cancer. 1997;76(3):299–305. doi: 10.1038/bjc.1997.382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Harper J. W., Adami G. R., Wei N., Keyomarsi K., Elledge S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993 Nov 19;75(4):805–816. doi: 10.1016/0092-8674(93)90499-g. [DOI] [PubMed] [Google Scholar]
  17. Hirvikoski P., Kumpulainen E., Virtaniemi J., Johansson R., Haapasalo H., Marin S., Halonen P., Helin H., Raitiola H., Pukander J. p53 expression and cell proliferation as prognostic factors in laryngeal squamous cell carcinoma. J Clin Oncol. 1997 Sep;15(9):3111–3120. doi: 10.1200/JCO.1997.15.9.3111. [DOI] [PubMed] [Google Scholar]
  18. Ito K., Sasano H., Matsunaga G., Sato S., Yajima A., Nasim S., Garret C. T. Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma. J Pathol. 1997 Nov;183(3):318–324. doi: 10.1002/(SICI)1096-9896(199711)183:3<318::AID-PATH925>3.0.CO;2-0. [DOI] [PubMed] [Google Scholar]
  19. Kawasaki T., Tomita Y., Bilim V., Takeda M., Takahashi K., Kumanishi T. Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations. Int J Cancer. 1996 Nov 15;68(4):501–505. doi: 10.1002/(SICI)1097-0215(19961115)68:4<501::AID-IJC16>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  20. Komiya T., Hosono Y., Hirashima T., Masuda N., Yasumitsu T., Nakagawa K., Kikui M., Ohno A., Fukuoka M., Kawase I. p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin Cancer Res. 1997 Oct;3(10):1831–1835. [PubMed] [Google Scholar]
  21. Melhem M. F., Law J. C., el-Ashmawy L., Johnson J. T., Landreneau R. J., Srivastava S., Whiteside T. L. Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. Am J Pathol. 1995 May;146(5):1170–1177. [PMC free article] [PubMed] [Google Scholar]
  22. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  23. Miyashita T., Krajewski S., Krajewska M., Wang H. G., Lin H. K., Liebermann D. A., Hoffman B., Reed J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994 Jun;9(6):1799–1805. [PubMed] [Google Scholar]
  24. Moskaluk C. A., Heitmiller R., Zahurak M., Schwab D., Sidransky D., Hamilton S. R. p53 and p21(WAF1/CIP1/SDI1) gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction. Hum Pathol. 1996 Nov;27(11):1211–1220. doi: 10.1016/s0046-8177(96)90317-2. [DOI] [PubMed] [Google Scholar]
  25. Nadal A., Jares P., Cazorla M., Fernández P. L., Sanjuan X., Hernandez L., Pinyol M., Aldea M., Mallofré C., Muntané J. p21WAF1/Cip1 expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx. J Pathol. 1997 Oct;183(2):156–163. doi: 10.1002/(SICI)1096-9896(199710)183:2<156::AID-PATH908>3.0.CO;2-O. [DOI] [PubMed] [Google Scholar]
  26. Ohashi K., Nemoto T., Eishi Y., Matsuno A., Nakamura K., Hirokawa K. Expression of the cyclin dependent kinase inhibitor p21WAF1/CIP1 in oesophageal squamous cell carcinomas. Virchows Arch. 1997 May;430(5):389–395. doi: 10.1007/s004280050048. [DOI] [PubMed] [Google Scholar]
  27. Ory K., Legros Y., Auguin C., Soussi T. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J. 1994 Aug 1;13(15):3496–3504. doi: 10.1002/j.1460-2075.1994.tb06656.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Pruneri G., Pignataro L., Carboni N., Luminari S., Capaccio P., Neri A., Buffa R. MDM-2 oncoprotein overexpression in laryngeal squamous cell carcinoma: association with wild-type p53 accumulation. Mod Pathol. 1997 Aug;10(8):785–792. [PubMed] [Google Scholar]
  29. Pruneri G., Pignataro L., Carboni N., Ronchetti D., Cesana B. M., Ottaviani A., Neri A., Buffa R. Clinical relevance of p53 and bcl-2 protein over-expression in laryngeal squamous-cell carcinoma. Int J Cancer. 1998 Jun 19;79(3):263–268. doi: 10.1002/(sici)1097-0215(19980619)79:3<263::aid-ijc9>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  30. Spafford M. F., Koeppe J., Pan Z., Archer P. G., Meyers A. D., Franklin W. A. Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1996 Jun;122(6):627–632. doi: 10.1001/archotol.1996.01890180035010. [DOI] [PubMed] [Google Scholar]
  31. Tron V. A., Tang L., Yong W. P., Trotter M. J. Differentiation-associated overexpression of the cyclin-dependent kinase inhibitor p21waf-1 in human cutaneous squamous cell carcinoma. Am J Pathol. 1996 Oct;149(4):1139–1146. [PMC free article] [PubMed] [Google Scholar]
  32. Wakasugi E., Kobayashi T., Tamaki Y., Ito Y., Miyashiro I., Komoike Y., Takeda T., Shin E., Takatsuka Y., Kikkawa N. p21(Waf1/Cip1) and p53 protein expression in breast cancer. Am J Clin Pathol. 1997 Jun;107(6):684–691. doi: 10.1093/ajcp/107.6.684. [DOI] [PubMed] [Google Scholar]
  33. Wang A., Yoshimi N., Ino N., Tanaka T., Mori H. WAF1 expression and p53 mutations in human colorectal cancers. J Cancer Res Clin Oncol. 1997;123(2):118–123. doi: 10.1007/BF01269890. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Werness B. A., Wang H. Q., Chance J., Goldstein D. J. p53-independent expression of p21waf1/cip1 in preinvasive and invasive squamous neoplasms of the uterine cervix. Mod Pathol. 1997 Jun;10(6):578–584. [PubMed] [Google Scholar]
  35. Yasui W., Akama Y., Kuniyasu H., Yokozaki H., Semba S., Shimamoto F., Tahara E. Expression of cyclin-dependent kinase inhibitor p21WAF1/CIP1 in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity. J Pathol. 1996 Oct;180(2):122–128. doi: 10.1002/(SICI)1096-9896(199610)180:2<122::AID-PATH647>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  36. el-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993 Nov 19;75(4):817–825. doi: 10.1016/0092-8674(93)90500-p. [DOI] [PubMed] [Google Scholar]
  37. el-Deiry W. S., Tokino T., Waldman T., Oliner J. D., Velculescu V. E., Burrell M., Hill D. E., Healy E., Rees J. L., Hamilton S. R. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res. 1995 Jul 1;55(13):2910–2919. [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES